Alex Johnson brings broad international business experience in pharma and clinical diagnostics. Prior to joining CareDx, Alex was Chief Operating Officer of BioGraph 55, a venture-backed immuno-oncology drug development company that uses advanced imaging analytics and machine learning to capture clinically relevant content from the tumor microenvironment. From 2009 to 2014 he was with Novartis, with roles at Novartis Diagnostics, a global provider of blood screening solutions and Novartis M&A based in Basel, Switzerland where he led acquisitions in oncology and diagnostics. Prior to Novartis Alex was with UBS Investment Bank in the Global Healthcare group. Mr. Johnson studied economics at Union College (NY) and received his M.B.A. in Finance from Columbia Business School.